Skip to main content

Advertisement

Springer Nature Link
Log in

Gynecologic Cancer Screening and Prevention: State of the Science and Practice

  • REVIEW
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion Statement

Gynecological cancers, including cervical, endometrial, ovarian, and vulvovaginal cancer, have increasing incidence and mortality globally over the last three decades. In that time, there have been advances in medical therapies and paradigm shifts in surgical treatment which have resulted in a greater quality of life for patients. Clinicians have also refocused efforts to preventing gynecologic cancer. The state of screening and prevention is varied in each of the cancer types. The most comprehensive screening program and only preventable gynecological cancer is cervical cancer, which has been heavily studied since the 1900s. Cervical cytology, primary high-risk human papillomavirus (HPV) testing only, and co-testing are all effective in detecting cervical dysplasia and touted by the major medical. An additional arsenal is prevention through vaccination which has been shown to decrease cervical cancer. Unfortunately, the other gynecological cancers do not have effective screening strategies. The high rates of symptoms in endometrial cancer facilitate detection at an early stage but thus far, asymptomatic screening is only advocated in very high-risk population due to the invasive nature. Novel non-invasive mechanisms are currently under study though none have translated into clinical practice as of yet. Ovarian cancer remains the most innocuous with vague symptoms at onset resulting in late-stage diagnosis. Recommendations for prophylactic oophorectomy only apply to subsets of the population with predisposing genetic mutations. This has led to an ardent push for creative strategies such as opportunistic salpingectomy and a national genetic screening program. These efforts are in addition to the investigations underway researching radiologic, liquid biopsy, and genetic marker screening modalities for all gynecologic cancer. This review article discusses the state of screening, prevention, and recent advancements and pilot studies for each gynecological cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

Data Availability

No datasets were generated or analysed during the current study.

References and Recommended Reading

  1. Yi M, Li T, Niu M, Luo S, Chu Q, Wu K. Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomark Res. 2021;9:55. https://doi.org/10.1186/s40364-021-00310-y.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Common Cancer Sites — Cancer Stat Facts n.d. https://seer.cancer.gov/statfacts/html/common.html (accessed January 4, 2025).

  3. Research C for DE. FDA approves bevacizumab in combination with chemotherapy for ovarian cancer. FDA. 2024.

  4. Research C for DE. FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer. FDA. 2024.

  5. Sharp M, Dohme. Keytruda (Pembrolizumab). n.d.

  6. Research C for DE. FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer. FDA. 2023.

  7. Research C for DE. FDA grant accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. FDA. 2024.

  8. Research C for DE. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA. 2024.

  9. Research C for DE. FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. FDA. 2024.

  10. Eifel PJ, Klopp AH, Berek JS, Konstantinopoulos PA. Cancer of the cervix, vagina, and vulva. DeVita Hellman Rosenb. Cancer Princ. Pract. Oncol., Wolters Kluwer Health Pharma Solutions (Europe) Ltd; 2018, pp. 1172–210.

  11. Jhingran A, Russell AH, Seiden MV, Duska LR, Goodman A, Lee SL, et al. Cancers of the Cervix, Vulva, and Vagina. Abeloff’s Clin. Oncol., Elsevier; 2019, p. 1468–1507.e8. https://doi.org/10.1016/B978-0-323-47674-4.00084-0.

  12. Benoit M, Williams-Brown MY, Edwards C. Gynecologic oncology handbook: An evidence-based clinical guide. 3rd ed. Springer; 2022.

  13. Jenkins D. Chapter 1 - A Brief History of Cervical Cancer. In: Jenkins D, Bosch FX, editors. Hum. Papillomavirus, Academic Press; 2020, 1–12. https://doi.org/10.1016/B978-0-12-814457-2.00001-5.

  14. Jordan JA. 6 - The Diagnosis and Management of Premalignant Conditions of the Cervix. Clin Obstet Gynaecol. 1976;3:295–315. https://doi.org/10.1016/S0306-3356(21)00347-2.

    Article  CAS  PubMed  Google Scholar 

  15. Thoms H. Diagnosis of Uterine Cancer by the Vaginal Smear. Yale J Biol Med. 1943;15:924.

    PubMed Central  Google Scholar 

  16. Vilos GA. The history of the Papanicolaou smear and the odyssey of George and Andromache Papanicolaou. Obstet Gynecol. 1998;91:479–83. https://doi.org/10.1016/s0029-7844(97)00695-9.

    Article  CAS  PubMed  Google Scholar 

  17. History of Surgical Treatment for Cervical Intraepithelial Neoplasia | Journal of Gynecologic Surgery n.d. https://www.liebertpub.com/doi/https://doi.org/10.1089/gyn.2021.0138 (accessed January 4, 2025).

  18. US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320:674–86. https://doi.org/10.1001/jama.2018.10897.

    Article  Google Scholar 

  19. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70:321–46. https://doi.org/10.3322/caac.21628.

    Article  PubMed  Google Scholar 

  20. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349–59. https://doi.org/10.1002/ijc.27485.

    Article  CAS  PubMed  Google Scholar 

  21. Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020;24:102–31. https://doi.org/10.1097/LGT.0000000000000525.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Updated Cervical Cancer Screening Guidelines n.d. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines (accessed January 4, 2025).

  23. Silver MI, Schiffman M, Fetterman B, Poitras NE, Gage JC, Wentzensen N, et al. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. Cancer. 2016;122:3682–6. https://doi.org/10.1002/cncr.30277.

    Article  PubMed  Google Scholar 

  24. Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, et al. Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. J Natl Cancer Inst. 2018;110:501–8. https://doi.org/10.1093/jnci/djx225.

    Article  PubMed  Google Scholar 

  25. Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology. 2020;76:112–27. https://doi.org/10.1111/his.13995.

    Article  PubMed  Google Scholar 

  26. Safaeian M, Solomon D. Cervical Cancer Prevention - Cervical Screening: Science in Evolution. Obstet Gynecol Clin North Am. 2007;34:739–ix. https://doi.org/10.1016/j.ogc.2007.09.004.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Updates on cervical cancer prevention - PubMed n.d. https://pubmed.ncbi.nlm.nih.gov/36878567/ (accessed January 4, 2025).

  28. Siddiqui MAA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006;66:1263–71; discussion 1272–1273. https://doi.org/10.2165/00003495-200666090-00008.

  29. CervarixTM: a vaccine for the prevention of HPV 16, 18-associated cervical cancer - PMC n.d. https://pmc.ncbi.nlm.nih.gov/articles/PMC2727782/ (accessed January 4, 2025).

  30. Research C for BE. GARDASIL 9. FDA. 2024.

  31. Cervarix - withdrawal of application for variation to marketing authorisation | European Medicines Agency (EMA) 2021. https://www.ema.europa.eu/en/medicines/human/variation/cervarix (accessed January 4, 2025).

  32. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;5:CD009069. https://doi.org/10.1002/14651858.CD009069.pub3.

  33. Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383:1340–8. https://doi.org/10.1056/NEJMoa1917338.

    Article  CAS  PubMed  Google Scholar 

  34. Larson HJ, Wilson R, Hanley S, Parys A, Paterson P. Tracking the global spread of vaccine sentiments: the global response to Japan’s suspension of its HPV vaccine recommendation. Hum Vaccines Immunother. 2014;10:2543–50. https://doi.org/10.4161/21645515.2014.969618.

    Article  Google Scholar 

  35. Yagi A, Ueda Y, Kakuda M, Tanaka Y, Ikeda S, Matsuzaki S, et al. Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry. Cancer Res. 2019;79:1252–9. https://doi.org/10.1158/0008-5472.CAN-18-3109.

    Article  CAS  PubMed  Google Scholar 

  36. Nakagawa S, Ueda Y, Yagi A, Ikeda S, Hiramatsu K, Kimura T. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan. Cancer Sci. 2020;111:2156–62. https://doi.org/10.1111/cas.14406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sekine M, Yamaguchi M, Kudo R, Hanley SJB, Ueda Y, Kurosawa M, et al. Problems with catch-up HPV vaccination after resumption of proactive recommendations. Lancet Oncol. 2022;23:972–3. https://doi.org/10.1016/S1470-2045(22)00259-5.

    Article  CAS  PubMed  Google Scholar 

  38. Global strategy to accelerate the elimination of cervical cancer as a public health problem n.d. https://www.who.int/publications/i/item/9789240014107 (accessed January 4, 2025).

  39. Elam-Evans LD, Yankey D, Singleton JA, Sterrett N, Markowitz LE, Williams CL, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years - United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:1109–16. https://doi.org/10.15585/mmwr.mm6933a1.

  40. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590.

    Article  PubMed  Google Scholar 

  41. Bharel M, Casey C, Wittenberg E. Disparities in cancer screening: acceptance of Pap smears among homeless women. J Womens Health. 2002;2009(18):2011–6. https://doi.org/10.1089/jwh.2008.1111.

    Article  Google Scholar 

  42. Cancer of the Cervix Uteri - Cancer Stat Facts. SEER n.d. https://seer.cancer.gov/statfacts/html/cervix.html (accessed January 4, 2025).

  43. Crosby RA, Casey BR, Vanderpool R, Collins T, Moore GR. Uptake of free HPV vaccination among young women: a comparison of rural versus urban rates. J Rural Health Off J Am Rural Health Assoc Natl Rural Health Care Assoc. 2011;27:380–4. https://doi.org/10.1111/j.1748-0361.2010.00354.x.

    Article  Google Scholar 

  44. National Comprehensive Cancer Network. NCCN clincial practice guidelines in oncology. Cervical Cancer (Version 1.2025). 2024.

  45. Athanasiou A, Veroniki AA, Efthimiou O, Kalliala I, Naci H, Bowden S, et al. Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. Lancet Oncol. 2022;23:1097–108. https://doi.org/10.1016/S1470-2045(22)00334-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis. 2013;17:S78-84. https://doi.org/10.1097/LGT.0b013e31828543c5.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Yabroff KR, Lawrence WF, King JC, Mangan P, Washington KS, Yi B, et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health Off J Am Rural Health Assoc Natl Rural Health Care Assoc. 2005;21:149–57. https://doi.org/10.1111/j.1748-0361.2005.tb00075.x.

    Article  Google Scholar 

  48. Desravines N, Miele K, Carlson R, Chibwesha C, Rahangdale L. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2–3: A narrative review. Gynecol Oncol Rep. 2020;33:100608. https://doi.org/10.1016/j.gore.2020.100608.

    Article  PubMed  PubMed Central  Google Scholar 

  49. van de Sande AJM, van Baars R, Koeneman MM, Gerestein CG, Kruse A-J, van Esch EMG, et al. Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trial. BJOG Int J Obstet Gynaecol. 2024;https://doi.org/10.1111/1471-0528.17808.

  50. van de Laar RLO, Hofhuis W, Duijnhoven RG, Polinder S, Melchers WJG, van Kemenade FJ, et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. BMC Cancer. 2020;20:539. https://doi.org/10.1186/s12885-020-07025-7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Laar RVD, Hofhuis W, Duijnhoven R, Beekhuizen HV. LB013/#1571 Adjuvant vaccination against HPV in surgical treatment of CIN lesions: results of the vaccin-study, a randomised placebo-controlled trial. Int J Gynecol Cancer 2024;34. https://doi.org/10.1136/ijgc-2024-IGCS.11.

  52. Giannella L, Ciavattini A. Screening and Early Diagnosis in Gynecological Cancers. Cancers. 2023;15:5152. https://doi.org/10.3390/cancers15215152.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Endometrial Cancer n.d. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2015/04/endometrial-cancer (accessed January 4, 2025).

  54. Shen Y, Yang W, Liu J, Zhang Y. Minimally invasive approaches for the early detection of endometrial cancer. Mol Cancer. 2023;22:53. https://doi.org/10.1186/s12943-023-01757-3.

    Article  PubMed  PubMed Central  Google Scholar 

  55. ACOG Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. 2018;131:e124-9. https://doi.org/10.1097/AOG.0000000000002631.

    Article  Google Scholar 

  56. Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals | Reproductive Health | JAMA Oncology | JAMA Network n.d. https://jamanetwork.com/journals/jamaoncology/article-abstract/2820528 (accessed January 4, 2025).

  57. Romano SS, Doll KM. The Impact of Fibroids and Histologic Subtype on the Performance of US Clinical Guidelines for the Diagnosis of Endometrial Cancer among Black Women. Ethn Dis. 2020;30:543–52. https://doi.org/10.18865/ed.30.4.543.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Di Spiezio SA, Saccone G, Carugno J, Pacheco LA, Zizolfi B, Haimovich S, et al. Endometrial biopsy under direct hysteroscopic visualisation versus blind endometrial sampling for the diagnosis of endometrial hyperplasia and cancer: Systematic review and meta-analysis. Facts Views Vis ObGyn. 2022;14:103–10. https://doi.org/10.52054/FVVO.14.2.023.

    Article  Google Scholar 

  59. Lorentzen GM, Łaniewski P, Cui H, Mahnert ND, Mourad J, Borst MP, et al. Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification. Clin Cancer Res. 2024;30:3073–87. https://doi.org/10.1158/1078-0432.CCR-23-2934.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Njoku K, Pierce A, Chiasserini D, Geary B, Campbell AE, Kelsall J, et al. Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery. eBioMedicine 2024;102:105064. https://doi.org/10.1016/j.ebiom.2024.105064.

  61. Bakkum-Gamez JN, Sherman ME, Slettedahl SW, Mahoney DW, Lemens MA, Laughlin-Tommaso SK, et al. Detection of Endometrial Cancer Using Tampon-Based Collection and Methylated DNA Markers. Gynecol Oncol. 2023;174:11–20. https://doi.org/10.1016/j.ygyno.2023.04.014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Evans I, Reisel D, Jones A, Bajrami A, Nijjar S, Solangon SA, et al. Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK. Lancet Oncol. 2023;24:1375–86. https://doi.org/10.1016/S1470-2045(23)00466-7.

    Article  PubMed  Google Scholar 

  63. O’Flynn H, Ryan NAJ, Narine N, Shelton D, Rana D, Crosbie EJ. Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples. Nat Commun. 2021;12:952. https://doi.org/10.1038/s41467-021-21257-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. DEveloping Tests for Endometrial Cancer deTection (DETECT): protocol for a diagnostic accuracy study of urine and vaginal samples for the detection of endometrial cancer by cytology in women with postmenopausal bleeding | BMJ Open n.d. https://bmjopen.bmj.com/content/11/7/e050755 (accessed January 4, 2025).

  65. Zhong W, Liu Y, Zhang L, Zhuang W, Chen J, Huang Z, et al. Combination of serum CST1 and HE4 for early diagnosis of endometrial cancer. PeerJ. 2023;11:e16424. https://doi.org/10.7717/peerj.16424.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, Hu P, et al. Targeted next-generation sequencing of endometrial cancer and matched circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol. 2019;32:405–14. https://doi.org/10.1038/s41379-018-0158-8.

    Article  CAS  PubMed  Google Scholar 

  67. Baker-Rand H, Kitson SJ. Recent Advances in Endometrial Cancer Prevention. Early Diagnosis and Treatment Cancers. 2024;16:1028. https://doi.org/10.3390/cancers16051028.

    Article  CAS  PubMed  Google Scholar 

  68. Lynch Syndrome n.d. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2014/11/lynch-syndrome (accessed November 13, 2024).

  69. Chelmow D, Brooks R, Cavens A, Huber-Keener K, Scott DM, Sheth SS, et al. Executive Summary of the Uterine Cancer Evidence Review Conference. Obstet Gynecol. 2022;139:626. https://doi.org/10.1097/AOG.0000000000004711.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers | Cancer Prevention Research | American Association for Cancer Research n.d. https://aacrjournals.org/cancerpreventionresearch/article/16/11/611/729696/Methylated-DNA-Markers-for-Sporadic-Colorectal-and (accessed January 4, 2025).

  71. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol 2017;130:e110–26. https://doi.org/10.1097/AOG.0000000000002296.

  72. Incidence of endometrial cancer in BRCA mutation carriers - Gynecologic Oncology n.d. https://www.gynecologiconcology-online.net/article/S0090-8258(24)01052-7/abstract (accessed January 4, 2025).

  73. Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N, PHTS Guideline Development Group, European Reference Network GENTURIS. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet EJHG 2020;28:1387–93. https://doi.org/10.1038/s41431-020-0651-7.

  74. USCS Data Visualizations n.d. https://gis.cdc.gov/grasp/USCS/DataViz.html (accessed December 6, 2024).

  75. Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer1. Obstet Gynecol. 2001;98:212–7. https://doi.org/10.1016/S0029-7844(01)01457-0.

    Article  CAS  PubMed  Google Scholar 

  76. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–75. https://doi.org/10.1002/1097-0142(20001115)89:10%3c2068::AID-CNCR6%3e3.0.CO;2-Z.

    Article  CAS  PubMed  Google Scholar 

  77. Goodman MT, Correa CN, Tung K-H, Roffers SD, Cheng WuX, Young JL, et al. Stage at diagnosis of ovarian cancer in the United States, 1992–1997. Cancer. 2003;97:2648–59. https://doi.org/10.1002/cncr.11347.

    Article  PubMed  Google Scholar 

  78. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer. NCCN n.d. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453 (accessed November 12, 2024).

  79. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295–303. https://doi.org/10.1001/jama.2011.766.

    Article  CAS  PubMed  Google Scholar 

  80. Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193:1630–9. https://doi.org/10.1016/j.ajog.2005.05.005.

    Article  PubMed  Google Scholar 

  81. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993;85:1748–51. https://doi.org/10.1093/jnci/85.21.1748.

    Article  CAS  PubMed  Google Scholar 

  82. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001;92:2837–44. https://doi.org/10.1002/1097-0142(20011201)92:11%3c2837::aid-cncr10093%3e3.0.co;2-5.

    Article  PubMed  Google Scholar 

  83. Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol. 2005;58:308–12. https://doi.org/10.1136/jcp.2004.018077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers. 2020;12:3730. https://doi.org/10.3390/cancers12123730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Sopik V, Rosen B, Giannakeas V, Narod SA. Why have ovarian cancer mortality rates declined? Part III. Prospects for the future Gynecol Oncol. 2015;138:757–61. https://doi.org/10.1016/j.ygyno.2015.06.019.

    Article  PubMed  Google Scholar 

  86. Kamal R, Hamed S, Mansour S, Mounir Y, Sallam SA. Ovarian cancer screening—ultrasound; impact on ovarian cancer mortality. Br J Radiol. 2018;91:20170571. https://doi.org/10.1259/bjr.20170571.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet Lond Engl. 2016;387:945–56. https://doi.org/10.1016/S0140-6736(15)01224-6.

    Article  Google Scholar 

  88. Skates SJ. OCS: Development of the Risk of Ovarian Cancer Algorithm (ROCA) and ROCA screening trials. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2012;22:S24-6. https://doi.org/10.1097/IGC.0b013e318256488a.

    Article  Google Scholar 

  89. Han CY, Lu KH, Bedi D, Bedia E, Bevers TB, Holman LL, et al. The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update. J Clin Oncol. 2023;41:5522–5522. https://doi.org/10.1200/JCO.2023.41.16_suppl.5522.

    Article  Google Scholar 

  90. Sundar S, Agarwal R, Davenport C, Scandrett K, Johnson S, Sengupta P, et al. Risk-prediction models in postmenopausal patients with symptoms of suspected ovarian cancer in the UK (ROCkeTS): a multicentre, prospective diagnostic accuracy study. Lancet Oncol. 2024;25:1371–86. https://doi.org/10.1016/S1470-2045(24)00406-6.

    Article  CAS  PubMed  Google Scholar 

  91. Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol. 2017;216:270.e1-270.e9. https://doi.org/10.1016/j.ajog.2016.10.035.

    Article  PubMed  Google Scholar 

  92. Desravines N, Brenner T, Venkatesh K, Stuart G. Frequency and characteristics associated with opportunistic salpingectomy at cesarean delivery: A retrospective chart review. Contraception. 2021;103:203–7. https://doi.org/10.1016/j.contraception.2020.12.001.

    Article  PubMed  Google Scholar 

  93. Ostby SA, Blanchard CT, Sanjanwala AR, Szychowski JM, Leath CA, Huh WK, et al. Feasibility, Safety, and Provider Perspectives of Bipolar Electrosurgical Cautery Device for (Opportunistic or Complete) Salpingectomy at the Time of Cesarean Delivery. Am J Perinatol. 2024;41:804–13. https://doi.org/10.1055/s-0042-1748525.

    Article  PubMed  Google Scholar 

  94. Stone R, Sakran JV, Long RK. Salpingectomy in Ovarian Cancer Prevention. JAMA. 2023;329:2015–6. https://doi.org/10.1001/jama.2023.6979.

    Article  PubMed  Google Scholar 

  95. Kather A, Arefian H, Schneider C, Hartmann M, Runnebaum IB. Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effectiveness modeling study. PLoS Med. 2025;22:e1004514. https://doi.org/10.1371/journal.pmed.1004514.

    Article  PubMed  PubMed Central  Google Scholar 

  96. MacArthur E, Long Roche K, Sakran J, Patel SH, Najjar P, Lu KH, et al. Salpingectomy for ovarian cancer prevention: Video education for the surgeon. Gynecol Oncol Rep. 2024;53:101368. https://doi.org/10.1016/j.gore.2024.101368.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Neesham D. Ovarian cancer screening. Aust Fam Physician. 2007;36:126–8.

    PubMed  Google Scholar 

  98. Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J Clin Oncol. 2019;37:453–60. https://doi.org/10.1200/JCO.18.01631.

    Article  PubMed  Google Scholar 

  99. Torr B, Bell N, McCarthy R, Hamill M, Nolan J, Muralidharan S, et al. The NHS England Jewish BRCA Testing Programme: overview after first year of implementation (2023–2024). J Med Genet. 2024. https://doi.org/10.1136/jmg-2024-110390.

    Article  PubMed  Google Scholar 

  100. PROTECT-C. Prot-C n.d. https://www.protect-c.co.uk (accessed January 5, 2025).

  101. Takeda T, Tsuji K, Banno K, Yanokura M, Kobayashi Y, Tominaga E, et al. Screening for Lynch syndrome using risk assessment criteria in patients with ovarian cancer. J Gynecol Oncol. 2018;29: e29. https://doi.org/10.3802/jgo.2018.29.e29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Walker M, Jacobson M, Sobel M. Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants. CMAJ Can Med Assoc J. 2019;191:E886-93. https://doi.org/10.1503/cmaj.190281.

    Article  Google Scholar 

  103. Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, et al. Risk assessment, genetic counseling, and genetic testing for brca-related cancer: Systematic review to update the U.S. preventive services task force recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.

  104. Ain QU, Muhammad S, Hai Y, Peiling L. The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours. J Obstet Gynaecol J Inst Obstet Gynaecol. 2022;42:3441–9. https://doi.org/10.1080/01443615.2022.2151352.

    Article  Google Scholar 

  105. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40. https://doi.org/10.1016/S1470-2045(09)70026-9.

    Article  PubMed  Google Scholar 

  106. Woodward E, Sleightholme H, Considine A, Williamson S, McHugo J, Cruger D. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG Int J Obstet Gynaecol. 2007;114:1500–9. https://doi.org/10.1111/j.1471-0528.2007.01499.x.

    Article  CAS  Google Scholar 

  107. Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:1411–20. https://doi.org/10.1200/JCO.2016.69.9330.

    Article  Google Scholar 

  108. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7. https://doi.org/10.1093/jnci/djn442.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Watson P, Vasen HFA, Mecklin J-P, Bernstein I, Aarnio M, Järvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444–9. https://doi.org/10.1002/ijc.23508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. SEER Cancer Statistics Review 1975–2008 - Previous Version - SEER Cancer Statistics. SEER n.d. https://seer.cancer.gov/archive/csr/1975_2008/index.html (accessed December 6, 2024).

  111. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, et al. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer. 2008;113:326–35. https://doi.org/10.1002/cncr.23554.

    Article  PubMed  Google Scholar 

  112. Chen L, Yang KY, Little SE, Cheung MK, Caughey AB. Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families. Obstet Gynecol. 2007;110:18. https://doi.org/10.1097/01.AOG.0000267500.27329.85.

    Article  PubMed  Google Scholar 

  113. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand. 2011;90:437–44. https://doi.org/10.1111/j.1600-0412.2011.01091.x.

    Article  PubMed  Google Scholar 

  114. Lu Y, Li L. The Prognostic Value of Circulating Tumor DNA in Ovarian Cancer: A Meta-Analysis. Technol Cancer Res Treat. 2021;20:15330338211043784. https://doi.org/10.1177/15330338211043784.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Yin C, Luo C, Hu W, Ding X, Yuan C, Wang F. Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis. Dis Markers. 2016;2016:3825819. https://doi.org/10.1155/2016/3825819.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Zhang R, Shao F, Wu X, Ying K. Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer Amst Neth. 2010;69:225–31. https://doi.org/10.1016/j.lungcan.2009.11.009.

    Article  Google Scholar 

  117. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014;4:6269. https://doi.org/10.1038/srep06269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Fan G, Zhang K, Yang X, Ding J, Wang Z, Li J. Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review. PLoS ONE. 2017;12:e0171991. https://doi.org/10.1371/journal.pone.0171991.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, et al. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:2887–94. https://doi.org/10.1200/JCO.2017.77.6658.

    Article  CAS  Google Scholar 

  120. Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. PLoS Med. 2016;13:e1002198. https://doi.org/10.1371/journal.pmed.1002198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Karimi F, Azadbakht O, Veisi A, Sabaghan M, Owjfard M, Kharazinejad E, et al. Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis. Med Oncol. 2023;40:265. https://doi.org/10.1007/s12032-023-02128-0.

    Article  PubMed  Google Scholar 

  122. Key Statistics for Vaginal Cancer n.d. https://www.cancer.org/cancer/types/vaginal-cancer/about/key-statistics.html (accessed January 4, 2025).

  123. Di Donato V, Bellati F, Fischetti M, Plotti F, Perniola G, Benedetti PP. Vaginal cancer. Crit Rev Oncol Hematol. 2012;81:286–95. https://doi.org/10.1016/j.critrevonc.2011.04.004.

    Article  PubMed  Google Scholar 

  124. van de Nieuwenhof HP, Massuger LFAG, van der Avoort IAM, Bekkers RLM, Casparie M, Abma W, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009;45:851–6. https://doi.org/10.1016/j.ejca.2008.11.037.

    Article  PubMed  Google Scholar 

  125. Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia | PLOS ONE n.d. https://journals.plos.org/plosone/article?id=https://doi.org/10.1371/journal.pone.0167386 (accessed January 4, 2025).

  126. The risk of vaginal, vulvar and anal precancer and cancer according to high‐risk HPV status in cervical cytology samples - Lindquist - 2024 - International Journal of Cancer - Wiley Online Library n.d. https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/ijc.34896 (accessed January 4, 2025).

  127. Adams TS, Rogers LJ, Cuello MA. Cancer of the vagina: 2021 update. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2021;155(Suppl 1):19–27. https://doi.org/10.1002/ijgo.13867.

    Article  Google Scholar 

  128. Olawaiye AB, Cuello MA, Rogers LJ. Cancer of the vulva: 2021 update. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2021;155(Suppl 1):7–18. https://doi.org/10.1002/ijgo.13881.

    Article  Google Scholar 

Download references

Acknowledgements

No financial support was obtained in the production of this manuscript.

Author information

Authors and Affiliations

  1. Department of Women’s Health, University of Texas at Austin Dell Medical School, Austin, TX, USA

    C. Tran & H. Diaz-Ayllon

  2. College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA

    D. Abulez

  3. Dell Medical School, University of Texas at Austin, Austin, TX, USA

    S. Chinta

  4. Division of Gynecologic Oncology, Department of Women’s Health, University of Texas at Austin Dell Medical School, Health Discovery Building, 1601 N. Trinity Street, Austin, TX, USA

    MY. Williams-Brown & N. Desravines

Authors
  1. C. Tran
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. H. Diaz-Ayllon
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. D. Abulez
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. S. Chinta
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. MY. Williams-Brown
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. N. Desravines
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

CT, HDA, DA, SD, and ND wrote the main manuscript text. DA prepared Table 1. MYWB and ND performed multiple edits of the manuscript and oversaw the formulation of the manuscript. All authors reviewed the manuscript.

Corresponding author

Correspondence to N. Desravines.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tran, C., Diaz-Ayllon, H., Abulez, D. et al. Gynecologic Cancer Screening and Prevention: State of the Science and Practice. Curr. Treat. Options in Oncol. 26, 167–178 (2025). https://doi.org/10.1007/s11864-025-01301-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-025-01301-z

Keywords